An observational study in Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Multiple Sclerosis by Novartis — 9 open to participants now, 23 under way, 6 of them phase 3. Multiple Sclerosis · Novartis.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 6th largest by enrollment of the 41 observational ones that give a count, is one of 4 that started in 2026, is one of 41 observational ones, and was the 106th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →9 of the 106 studies in Multiple Sclerosis by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 33 more countries
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 16 more countries
Ages 40–70
Novartis Pharmaceuticals · Sites in Greece
Ages 18–55
Novartis Pharmaceuticals · Sites in Switzerland
Ages 18+ · Women only
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 23 · Phase 4 26
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,607 is above the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 147 across the 64 interventional studies, 312 across the 41 observational. Of the 79 that completed or were terminated, 45 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
5 of the studies in Multiple Sclerosis by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07821411Novartis PharmaceuticalsA Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan | 2026-11-30 |
| NCT05776888Novartis PharmaceuticalsEarly Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years | 2026-12-16 |
| NCT07779460Novartis PharmaceuticalsA Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice | 2026-12-31 |
| NCT05809986Novartis PharmaceuticalsOfatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study | 2026-12-31 |
| NCT05090371Novartis PharmaceuticalsA Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation | 2027-04-13 |
Add all 5 to your calendar (.ics) → With an account.
Among the 106 studies in Multiple Sclerosis by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to assess the real-world patterns of disease modifying therapy (DMT) use before, during, and after pregnancy in women with multiple sclerosis (MS). The study will use a pooled closed claims database containing closed payer medical and pharmacy claims data for patients in the United States (US).
Women with a confirmed diagnosis of MS who had a live birth any time from August 20, 2020 to September 30, 2024 (identification period) or 6 months prior to end of study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
≥1 claim with a diagnosis or procedure code for live birth during the patient identification period (index date).
o Note: For patients with more than one pregnancy in the patient identification period, all eligible pregnancies will be included.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women with MS who experienced at least one live birth between August 20, 2020 and September 30, 2024.
Proportion of Patients With ≥1 DMT Claim During the Pre-Conception Period
Time frame: 6 months prior to the estimated conception date
Proportion of Patients With ≥1 DMT Claim During Pregnancy
Time frame: Day 0 to 90 (Trimester 1), Day 91 to 181 (Trimester 2), Day 182 up to and including the day before the delivery date (Trimester 3), and Day 0 up to approximately Day 280 (pregnancy period)
Proportion of Patients With ≥1 DMT Claim During the Post-Delivery Period
Time frame: Post-delivery 0 to 1.5 months, 1.5 to 3 months, 4 to 6 months, >6 months, up to approximately 4.5 years
Proportion of Patients by Demographic and Clinical Characteristics
Demographics and clinical characteristics include: * Age group * Race * Geographical region * Type of healthcare insurance coverage * Payer type * Year of index date * Mode of delivery * Use of fertility treatments * Deyo-Charlson Comorbidity Index (DCCI) category (0, 1-2, ≥3) * Psychological Diagnosis Group (PDG) * Comorbidities * MS-related symptoms and secondary conditions * MS disability (no disability symptoms, mild, moderate, severe)
Time frame: 6 months prior to the estimated conception date
DCCI Score
DCCI is an adaptation of the Charlson Comorbidity Index that uses diagnosis codes from administrative or claims data to quantify a patient's burden of comorbid conditions. It assigns weighted scores to a set of medical conditions based on their impact on mortality risk. DCCI scores start at 0, with higher scores indicating a greater number of and/or severe comorbid conditions.
Time frame: 6 months prior to the estimated conception date
Number of PDG Mental Health Disorders
PDG captures a list of mental health disorders a patient may have. The following are the list of PDGs: * Adult personality disorders * Anxiety disorders * Behavioral syndromes * Childhood and adolescent psychiatric syndromes * Intellectual disabilities * Psychiatric disorders with known physiological causes * Mood disorders * Pervasive disorders * Schizophrenia * Substance use
Time frame: 6 months prior to the estimated conception date
Age
Time frame: 6 months prior to the estimated conception date
Proportion of Patients by DMT Use During the Pre-Conception Period
Proportion of patients by type of DMT used during pre-conception reported by DMT class and generic name.
Time frame: 6 months prior to the estimated conception date
Proportion of Patients by DMT Use During Pregnancy
Proportion of patients by type of DMT used during pregnancy reported by DMT class and generic name.
Time frame: Day 0 to 90 (Trimester 1), Day 91 to 181 (Trimester 2), Day 182 up to and including the day before the delivery date (Trimester 3), and Day 0 up to approximately Day 280 (pregnancy period)
Proportion of Patients by DMT Use During the Post-Delivery Period
Proportion of patients by type of DMT used post-delivery reported by DMT class and generic name.
Time frame: Post-delivery 0 to 1.5 months, 1.5 to 3 months, 4 to 6 months, >6 months, up to approximately 4.5 years
Proportion of Patients by Sequences of DMTs Used During the Pre-Conception Period
Time frame: 6 months prior to the estimated conception date
Proportion of Patients by Sequences of DMTs Used During Pregnancy
Time frame: Day 0 to 90 (Trimester 1), Day 91 to 181 (Trimester 2), Day 182 up to and including the day before the delivery date (Trimester 3), and Day 0 up to approximately Day 280 (pregnancy period)
Proportion of Patients by Sequences of DMTs Used During the Post-Delivery Period
Time frame: Post-delivery 0 to 1.5 months, 1.5 to 3 months, 4 to 6 months, >6 months, up to approximately 4.5 years
Time to First Observed DMT Claim in the Post-Delivery Period
Time to first observed DMT claim in the post-delivery period among (a) patients without a DMT claim in the pre-conception or pregnancy periods (i.e., time to DMT initiation) and (b) patients with a DMT claim in the pre-conception and/or pregnancy periods (i.e., time to DMT continuation).
Time frame: Post-delivery 0 to 1.5 months, 1.5 to 3 months, 4 to 6 months, >6 months, up to approximately 4.5 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2026 to primary completion in Oct 2026, 7 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.